The FDA on February 9, 2023, approved JEMPERLIĀ® for adult patients with MisMatch Repair deficient (dMMR) recurrent or advanced Endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. JEMPERLIĀ® is a product of GlaxoSmithKline LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
